Associate Director, New Product Planning & Compound Strategy

Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.

Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients.

The Opportunity:

Reporting to the Executive Director, Head of Commercial Japan, the Associate Director, New Product Planning & Compound Strategy will lead commercial discipline for Revolution Medicines' lung cancer pipeline in Japan. This individual will lead Japan compound strategy, new product planning, and companion diagnostic (CDx) strategy across indications to maximize the commercial potential of pipeline assets and enable successful commercialization of precision oncology therapies.

Working across Commercial, Medical Affairs, Clinical Development, Market Access, Regulatory Affairs, Diagnostics, and Global teams, this role will translate established Japan and Global commercial strategy into integrated execution plans, influence key development and commercialization decisions, and lead execution across disciplines to ensure launch readiness and long-term portfolio success.

This position is based in Tokyo, Japan.

Responsibilities include:

Compound Strategy and Portfolio Planning

• Lead the Japan commercial discipline across cross-functional teams to develop integrated Japan compound strategies for lung cancer pipeline assets, ensuring alignment with overall corporate and commercial objectives.

• Lead development of compound-specific commercial strategies, incorporating customer insights, competitive intelligence, market dynamics, biomarker strategies, lifecycle planning, and portfolio prioritization.

• Partner with Global Commercial, Clinical Development, Medical Affairs, and Market Access to influence Target Product Profiles (TPPs), indication sequencing, evidence generation priorities, lifecycle management, and commercialization strategies.

• Identify highly complex commercial opportunities and business challenges that impact commercial success and translate insights into actionable strategic recommendations.

• Lead commercial assessments, forecasting assumptions, scenario planning, and business case development to support investment prioritization and portfolio decision-making.